Inflammation Research (2019) 68:427
https://doi.org/10.1007/s00011-019-01242-y

Inflammation Research

CORRECTION

Correction to: The IL-23p19/EBI3 heterodimeric cytokine termed IL-39 remains a theoretical cytokine in man

Charlie Bridgewood[1] · Adewonuola Alase[1] · Abdulla Watad[1,2,3] · Miriam Wittmann[1,4] · Richard Cuthbert[1] · Dennis McGonagle[1,4]

Published online: 7 May 2019

Correction to: Inflammation Research
https://doi.org/10.1007/s00011-019-01235-x

In the original publication, author correction was missed to incorporate under the section heading "Western blot and flow cytometry". The complete text is given here.

Western blot and flow cytometry

Cells were stimulated as before with IL-39 (100 ng/ml) or IL-6 (20 ng/ml) (Peprotech). Cells were lysed with CelLytic M lysis buffer (Sigma-Aldrich), containing protease inhibitor cocktail (Roche Applied Bioscience, Rotkreuz, Switzerland) and phosphatase inhibitor (Thermofisher). Protein concentration was determined by Bradford Assay, and 30 µg of total protein was separated on any kDa mini protean gel (Bio-Rad). Proteins were blotted onto 0.2 µm PVDF transblot pack (Bio-Rad). Membranes were incubated with either mouse anti-human GAPDH (Santa Cruz 1:10,000), mouse anti-human STAT3, or mouse anti-human phospho-STAT3 (both Cell Signaling, 1:1000), in 5% BSA/TBST overnight at 4 °C. Membranes were subsequently incubated with secondary antibody, HRP conjugated donkey anti-mouse (Santa Cruz, 1:5000) for 1 h at room temperature. Substrate solution A and B was from GE healthcare. For flow cytometry analysis, cells were stimulated as before. Using IntraPrep Permeabilization kit (Beckman Coulter) according to the manufacturer's instructions, cells were stained with mouse anti-human phospho-STAT3 or isotype control (PE-Cyanine7, eBioscience, both 1:50). Cells were analysed using the LSRII (BD Biosciences) and a FlowJo software (Tree Star Software, San Carlos, California, USA).

The original article has been corrected.

The original article can be found online at https://doi.org/10.1007/s00011-019-01235-x.

✉ Charlie Bridgewood
medcbri@leeds.ac.uk

[1] Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, UK

[2] Department of Medicine "B", Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Ramat Gan, Israel

[3] Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel

[4] National Institute for Health Research (NIHR) Leeds Biomedical Research Centre (BRC), Leeds Teaching Hospitals, Leeds, UK